In 45, ≤ 60 years old patients with CLL and an adverse biologic profile, a front-line treatment with Fludarabine and Campath (Alemtuzumab(®)) was given. The overall response rate was 75.5%, the complete response rate (CR) 24.4% with the lowest CR rates, 16.7% and 8.3%, in 11q and 17p deleted cases. The 3-year progression-free survival (PFS) and overall survival were 42.5% and 79.9%, respectively. PFS was significantly influenced by CLL duration, beta2-microglobulin, and improved by post-remissional stem cell transplantation. Front-line fludarabine and alemtuzumab showed a manageable safety profile and evidence of a benefit in a small series of CLL patients with adverse biologic features.
Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile / Mauro, Fr; Molica, S; Laurenti, L; Cortelezzi, A; Carella, Am; Zaja, F; Chiarenza, A; Angrilli, F; Nobile, F; Marasca, Roberto; Musolino, C; Brugiatelli, M; Piciocchi, A; Vignetti, M; Fazi, P; Gentile, G; De Propris, Ms; Della Starza, I; Marinelli, M; Chiaretti, S; Del Giudice, I; Nanni, M; Albano, F; Cuneo, A; Guarini, A; Foà, R.. - In: LEUKEMIA RESEARCH. - ISSN 0145-2126. - STAMPA. - 38:(2014), pp. 198-203. [10.1016/j.leukres.2013.11.009]
Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile
MARASCA, Roberto;
2014
Abstract
In 45, ≤ 60 years old patients with CLL and an adverse biologic profile, a front-line treatment with Fludarabine and Campath (Alemtuzumab(®)) was given. The overall response rate was 75.5%, the complete response rate (CR) 24.4% with the lowest CR rates, 16.7% and 8.3%, in 11q and 17p deleted cases. The 3-year progression-free survival (PFS) and overall survival were 42.5% and 79.9%, respectively. PFS was significantly influenced by CLL duration, beta2-microglobulin, and improved by post-remissional stem cell transplantation. Front-line fludarabine and alemtuzumab showed a manageable safety profile and evidence of a benefit in a small series of CLL patients with adverse biologic features.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Mauro Leuk Res (FluCam).pdf
Accesso riservato
Tipologia:
Versione pubblicata dall'editore
Dimensione
1.19 MB
Formato
Adobe PDF
|
1.19 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
